Bladder activity of different PSMA PET radioligands and impact of furosemide.

IF 1.7 Q3 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
American journal of nuclear medicine and molecular imaging Pub Date : 2026-04-25 eCollection Date: 2026-01-01 DOI:10.62347/KJRZ4126
Ismaheel Lawal, Aliza Mushtaq, Samuel N Gitau, Khalid Makhdomi, Manali Rupji, Jeffery M Switchenko, Krishna K Chaudhary, Ashesh B Jani, David M Schuster, Charles Marcus
{"title":"Bladder activity of different PSMA PET radioligands and impact of furosemide.","authors":"Ismaheel Lawal, Aliza Mushtaq, Samuel N Gitau, Khalid Makhdomi, Manali Rupji, Jeffery M Switchenko, Krishna K Chaudhary, Ashesh B Jani, David M Schuster, Charles Marcus","doi":"10.62347/KJRZ4126","DOIUrl":null,"url":null,"abstract":"<p><p>Prostate-specific membrane antigen (PSMA) radioligands used for PET imaging of prostate cancer (PCa) have variable urinary excretion. The prostate bed region is an important site of disease localization where intense bladder activity may obscure lesion detection. We performed a comparative analysis of bladder activity across different PSMA radioligands and investigated the impact of furosemide administration on reducing bladder activity. We analyzed the PSMA PET/CT images of patients with PCa who were imaged with <sup>68</sup>Ga-PSMA-11 with/without 20 mg furosemide, <sup>18</sup>F-PSMA-1007, <sup>18</sup>F-DCFPyL, <sup>18</sup>F-rhPSMA-7.3 with/without 20 mg furosemide. We determined and compared bladder volume and bladder activity level using mean and maximum standardized uptake values (SUV<sub>mean</sub> and SUV<sub>max</sub>) between PET scans obtained with the different PSMA radioligands using an ANOVA or Kruskal-Wallis test, as appropriate. We also determined the association between the bladder activity level versus bladder volume using Spearman correlation. 210 PSMA PET/CT studies were reviewed, including 50, 20, 20, 28, 42, and 50 completed with <sup>18</sup>F-PSMA-1007 without furosemide, <sup>18</sup>F-rhPSMA-7.3 without furosemide, <sup>18</sup>F-rhPSMA-7.3 with furosemide, <sup>68</sup>Ga-PSMA-11 without furosemide, <sup>68</sup>Ga-PSMA-11 with furosemide, and <sup>18</sup>F-DCFPyL without furosemide, respectively. The median bladder SUV<sub>mean</sub> (range) without furosemide were: 1.75 (0.4-6.4) [<sup>18</sup>F-PSMA-1007], 10.00 (1.9-140.0) [<sup>18</sup>F-rhPSMA-7.3], 15.92 (2.0-106.0) [<sup>68</sup>Ga-PSMA-11], and 25.7 (7.9-87.6) [<sup>18</sup>F-DCFPyL], (P<0.001). With 20 mg furosemide co-administered with the radiotracer, there was a significant decline in bladder activity level (median SUV<sub>mean</sub> of 10.00 (1.9-140.0) to 2.95 (0.8-17.6) for <sup>18</sup>F-rhPSMA-7.3 and 15.92 (2.0-106.0) to 10.21 (2.6-281.3) for <sup>68</sup>Ga-PSMA-11 and a significant increase in bladder volume, P<0.05. There was a significant negative correlation between bladder SUV<sub>max</sub> and bladder volume for the entire cohort, P=0.008, r=-0.181. There is variation in the bladder radioactivity between the different PSMA radioligands for PCa PET imaging, with <sup>18</sup>F-PSMA-1007 demonstrating the lowest, <sup>68</sup>Ga-PSMA-11 and <sup>18</sup>F-DCFPyL the highest, and <sup>18</sup>F-rhPSMA-7.3 intermediate bladder activity level. Administration of 20 mg furosemide produces a significant reduction in bladder activity and an increase in bladder volume. With 20 mg furosemide, bladder activity of <sup>18</sup>F-rhPSMA-7.3 approaches that of <sup>18</sup>F-PSMA-1007.</p>","PeriodicalId":7572,"journal":{"name":"American journal of nuclear medicine and molecular imaging","volume":"16 2","pages":"107-113"},"PeriodicalIF":1.7000,"publicationDate":"2026-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13191565/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of nuclear medicine and molecular imaging","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.62347/KJRZ4126","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0

Abstract

Prostate-specific membrane antigen (PSMA) radioligands used for PET imaging of prostate cancer (PCa) have variable urinary excretion. The prostate bed region is an important site of disease localization where intense bladder activity may obscure lesion detection. We performed a comparative analysis of bladder activity across different PSMA radioligands and investigated the impact of furosemide administration on reducing bladder activity. We analyzed the PSMA PET/CT images of patients with PCa who were imaged with 68Ga-PSMA-11 with/without 20 mg furosemide, 18F-PSMA-1007, 18F-DCFPyL, 18F-rhPSMA-7.3 with/without 20 mg furosemide. We determined and compared bladder volume and bladder activity level using mean and maximum standardized uptake values (SUVmean and SUVmax) between PET scans obtained with the different PSMA radioligands using an ANOVA or Kruskal-Wallis test, as appropriate. We also determined the association between the bladder activity level versus bladder volume using Spearman correlation. 210 PSMA PET/CT studies were reviewed, including 50, 20, 20, 28, 42, and 50 completed with 18F-PSMA-1007 without furosemide, 18F-rhPSMA-7.3 without furosemide, 18F-rhPSMA-7.3 with furosemide, 68Ga-PSMA-11 without furosemide, 68Ga-PSMA-11 with furosemide, and 18F-DCFPyL without furosemide, respectively. The median bladder SUVmean (range) without furosemide were: 1.75 (0.4-6.4) [18F-PSMA-1007], 10.00 (1.9-140.0) [18F-rhPSMA-7.3], 15.92 (2.0-106.0) [68Ga-PSMA-11], and 25.7 (7.9-87.6) [18F-DCFPyL], (P<0.001). With 20 mg furosemide co-administered with the radiotracer, there was a significant decline in bladder activity level (median SUVmean of 10.00 (1.9-140.0) to 2.95 (0.8-17.6) for 18F-rhPSMA-7.3 and 15.92 (2.0-106.0) to 10.21 (2.6-281.3) for 68Ga-PSMA-11 and a significant increase in bladder volume, P<0.05. There was a significant negative correlation between bladder SUVmax and bladder volume for the entire cohort, P=0.008, r=-0.181. There is variation in the bladder radioactivity between the different PSMA radioligands for PCa PET imaging, with 18F-PSMA-1007 demonstrating the lowest, 68Ga-PSMA-11 and 18F-DCFPyL the highest, and 18F-rhPSMA-7.3 intermediate bladder activity level. Administration of 20 mg furosemide produces a significant reduction in bladder activity and an increase in bladder volume. With 20 mg furosemide, bladder activity of 18F-rhPSMA-7.3 approaches that of 18F-PSMA-1007.

不同PSMA PET配体的膀胱活性及速尿的影响。
前列腺特异性膜抗原(PSMA)放射配体用于前列腺癌(PCa)的PET成像具有可变的尿排泄。前列腺床区是疾病定位的重要部位,强烈的膀胱活动可能使病变检测模糊不清。我们对不同PSMA放射配体的膀胱活动进行了比较分析,并研究了速尿给药对降低膀胱活动的影响。我们分析了68Ga-PSMA-11加/不加20mg呋塞米、18F-PSMA-1007、18F-DCFPyL、18F-rhPSMA-7.3加/不加20mg呋塞米的PCa患者的PSMA PET/CT图像。我们使用方差分析或Kruskal-Wallis检验(视情况而定),使用不同PSMA放射配体获得的PET扫描之间的平均和最大标准化摄取值(SUVmean和SUVmax)来确定和比较膀胱体积和膀胱活动水平。我们还利用Spearman相关性确定了膀胱活动水平与膀胱体积之间的关系。我们回顾了210项PSMA PET/CT研究,包括50、20、20、28、42和50项分别使用不含呋塞米的18F-PSMA-1007、不含呋塞米的18F-rhPSMA-7.3、不含呋塞米的18F-rhPSMA-7.3、不含呋塞米的68Ga-PSMA-11、不含呋塞米的68Ga-PSMA-11和不含呋塞米的18F-DCFPyL完成的研究。无速尿的膀胱SUVmean中位数(范围)分别为:1.75 (0.4-6.4)[18F-PSMA-1007]、10.00 (1.9-140.0)[18F-rhPSMA-7.3]、15.92 (2.0-106.0)[68Ga-PSMA-11]、25.7 (7.9-87.6)[18F-DCFPyL], 18F-rhPSMA-7.3的pvmean为10.00(1.9-140.0)至2.95 (0.8-17.6),68Ga-PSMA-11的pvmean为15.92(2.0-106.0)至10.21(2.6-281.3),整个队列的膀胱体积、Pmax和膀胱体积均显著增加,P=0.008, r=-0.181。不同PSMA配体的膀胱放射性在PCa PET成像中存在差异,其中18F-PSMA-1007最低,68Ga-PSMA-11和18F-DCFPyL最高,18F-rhPSMA-7.3处于膀胱活性中间水平。服用20mg速尿可显著减少膀胱活动,增加膀胱体积。使用20mg速尿时,18F-rhPSMA-7.3的膀胱活性接近18F-PSMA-1007。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
American journal of nuclear medicine and molecular imaging
American journal of nuclear medicine and molecular imaging RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING-
自引率
4.00%
发文量
4
期刊介绍: The scope of AJNMMI encompasses all areas of molecular imaging, including but not limited to: positron emission tomography (PET), single-photon emission computed tomography (SPECT), molecular magnetic resonance imaging, magnetic resonance spectroscopy, optical bioluminescence, optical fluorescence, targeted ultrasound, photoacoustic imaging, etc. AJNMMI welcomes original and review articles on both clinical investigation and preclinical research. Occasionally, special topic issues, short communications, editorials, and invited perspectives will also be published. Manuscripts, including figures and tables, must be original and not under consideration by another journal.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书